Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS

L F van der Voort; A Vennegoor; A Visser; D L Knol; B M J Uitdehaag; F Barkhof; C B M Oudejans; C H Polman; J Killestein

doi:https://doi.org/10.1212/WNL.0b013e3181f6c556

Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS

L F van der Voort, A Vennegoor, A Visser, D L Knol, B M J Uitdehaag, F Barkhof, C B M Oudejans, C H Polman, J Killestein

Neurology (AMC)

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

OBJECTIVE: To determine if myxovirus resistance protein A (MxA) mRNA is related to clinical disease activity in multiple sclerosis (MS).

METHODS: Baseline MxA mRNA levels were measured in a prospective cohort of 116 untreated patients with early MS and were related to clinical relapses and MRI at baseline and at follow-up.

RESULTS: Low levels of MxA mRNA were associated with the occurrence of relapses (p = 0.002) and contrast-enhancing lesions (CELs) on baseline MRI (p = 0.045). In addition, high baseline MxA mRNA levels were related to a longer time to a first new relapse (hazard ratio [HR] 0.59; 95% confidence interval [CI] 0.35-1.00; p = 0.044). Adding the absence of CELs to high MxA mRNA, the predictive value increased (HR 0.35; 95% CI 0.17-0.74; p = 0.006), clearly showing a cumulative value for combining both factors.

CONCLUSIONS: MxA mRNA is related to clinical exacerbations, the number of CELs on MRI, and is indicative for the time to a subsequent relapse. If confirmed, MxA mRNA has potential as a biomarker for clinical disease activity in MS.

Original language	English
Pages (from-to)	1228-33
Number of pages	6
Journal	Neurology
Volume	75
Issue number	14
DOIs	https://doi.org/10.1212/WNL.0b013e3181f6c556
Publication status	Published - 5 Oct 2010

Keywords

Adult
Antibodies, Neutralizing/therapeutic use
Cohort Studies
Disability Evaluation
Female
GTP-Binding Proteins/blood
Gene Expression Regulation/drug effects
Humans
Interferon-beta/therapeutic use
Magnetic Resonance Imaging/methods
Male
Middle Aged
Multiple Sclerosis, Relapsing-Remitting/blood
Myxovirus Resistance Proteins
Predictive Value of Tests
Proportional Hazards Models
RNA, Messenger/metabolism
ROC Curve
Regression Analysis
Young Adult

Access to Document

https://doi.org/10.1212/WNL.0b013e3181f6c556

Cite this

@article{3cef9468ab1e4371b30f9867b982d24c,

title = "Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS",

abstract = "OBJECTIVE: To determine if myxovirus resistance protein A (MxA) mRNA is related to clinical disease activity in multiple sclerosis (MS).METHODS: Baseline MxA mRNA levels were measured in a prospective cohort of 116 untreated patients with early MS and were related to clinical relapses and MRI at baseline and at follow-up.RESULTS: Low levels of MxA mRNA were associated with the occurrence of relapses (p = 0.002) and contrast-enhancing lesions (CELs) on baseline MRI (p = 0.045). In addition, high baseline MxA mRNA levels were related to a longer time to a first new relapse (hazard ratio [HR] 0.59; 95% confidence interval [CI] 0.35-1.00; p = 0.044). Adding the absence of CELs to high MxA mRNA, the predictive value increased (HR 0.35; 95% CI 0.17-0.74; p = 0.006), clearly showing a cumulative value for combining both factors.CONCLUSIONS: MxA mRNA is related to clinical exacerbations, the number of CELs on MRI, and is indicative for the time to a subsequent relapse. If confirmed, MxA mRNA has potential as a biomarker for clinical disease activity in MS.",

keywords = "Adult, Antibodies, Neutralizing/therapeutic use, Cohort Studies, Disability Evaluation, Female, GTP-Binding Proteins/blood, Gene Expression Regulation/drug effects, Humans, Interferon-beta/therapeutic use, Magnetic Resonance Imaging/methods, Male, Middle Aged, Multiple Sclerosis, Relapsing-Remitting/blood, Myxovirus Resistance Proteins, Predictive Value of Tests, Proportional Hazards Models, RNA, Messenger/metabolism, ROC Curve, Regression Analysis, Young Adult",

author = "{van der Voort}, {L F} and A Vennegoor and A Visser and Knol, {D L} and Uitdehaag, {B M J} and F Barkhof and Oudejans, {C B M} and Polman, {C H} and J Killestein",

year = "2010",

month = oct,

day = "5",

doi = "https://doi.org/10.1212/WNL.0b013e3181f6c556",

language = "English",

volume = "75",

pages = "1228--33",

journal = "Neurology",

issn = "0028-3878",

publisher = "American Academy of Neurology",

number = "14",

}

TY - JOUR

T1 - Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS

AU - van der Voort, L F

AU - Vennegoor, A

AU - Visser, A

AU - Knol, D L

AU - Uitdehaag, B M J

AU - Barkhof, F

AU - Oudejans, C B M

AU - Polman, C H

AU - Killestein, J

PY - 2010/10/5

Y1 - 2010/10/5

N2 - OBJECTIVE: To determine if myxovirus resistance protein A (MxA) mRNA is related to clinical disease activity in multiple sclerosis (MS).METHODS: Baseline MxA mRNA levels were measured in a prospective cohort of 116 untreated patients with early MS and were related to clinical relapses and MRI at baseline and at follow-up.RESULTS: Low levels of MxA mRNA were associated with the occurrence of relapses (p = 0.002) and contrast-enhancing lesions (CELs) on baseline MRI (p = 0.045). In addition, high baseline MxA mRNA levels were related to a longer time to a first new relapse (hazard ratio [HR] 0.59; 95% confidence interval [CI] 0.35-1.00; p = 0.044). Adding the absence of CELs to high MxA mRNA, the predictive value increased (HR 0.35; 95% CI 0.17-0.74; p = 0.006), clearly showing a cumulative value for combining both factors.CONCLUSIONS: MxA mRNA is related to clinical exacerbations, the number of CELs on MRI, and is indicative for the time to a subsequent relapse. If confirmed, MxA mRNA has potential as a biomarker for clinical disease activity in MS.

AB - OBJECTIVE: To determine if myxovirus resistance protein A (MxA) mRNA is related to clinical disease activity in multiple sclerosis (MS).METHODS: Baseline MxA mRNA levels were measured in a prospective cohort of 116 untreated patients with early MS and were related to clinical relapses and MRI at baseline and at follow-up.RESULTS: Low levels of MxA mRNA were associated with the occurrence of relapses (p = 0.002) and contrast-enhancing lesions (CELs) on baseline MRI (p = 0.045). In addition, high baseline MxA mRNA levels were related to a longer time to a first new relapse (hazard ratio [HR] 0.59; 95% confidence interval [CI] 0.35-1.00; p = 0.044). Adding the absence of CELs to high MxA mRNA, the predictive value increased (HR 0.35; 95% CI 0.17-0.74; p = 0.006), clearly showing a cumulative value for combining both factors.CONCLUSIONS: MxA mRNA is related to clinical exacerbations, the number of CELs on MRI, and is indicative for the time to a subsequent relapse. If confirmed, MxA mRNA has potential as a biomarker for clinical disease activity in MS.

KW - Adult

KW - Antibodies, Neutralizing/therapeutic use

KW - Cohort Studies

KW - Disability Evaluation

KW - Female

KW - GTP-Binding Proteins/blood

KW - Gene Expression Regulation/drug effects

KW - Humans

KW - Interferon-beta/therapeutic use

KW - Magnetic Resonance Imaging/methods

KW - Male

KW - Middle Aged

KW - Multiple Sclerosis, Relapsing-Remitting/blood

KW - Myxovirus Resistance Proteins

KW - Predictive Value of Tests

KW - Proportional Hazards Models

KW - RNA, Messenger/metabolism

KW - ROC Curve

KW - Regression Analysis

KW - Young Adult

U2 - https://doi.org/10.1212/WNL.0b013e3181f6c556

DO - https://doi.org/10.1212/WNL.0b013e3181f6c556

M3 - Article

C2 - 20921509

SN - 0028-3878

VL - 75

SP - 1228

EP - 1233

JO - Neurology

JF - Neurology

IS - 14

ER -